坎格列净片
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
INVOKANA® safely and effectively. See full prescribing information for
INVOKANA.
INVOKANA (canagliflozin) tablets, for oral use
Initial U.S. Approval: 2013
----------------------------INDICATIONS AND USAGE----------------------------
INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
indicated as an adjunct to diet and exercise to improve glycemic control in
adults with type 2 diabetes mellitus (1)
Limitation of Use:
! Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis (1)
-----------------------DOSAGE AND ADMINISTRATION-----------------------
! The recommended starting dose is 100 mg once daily, taken before the first
meal of the day (2.1)
! Dose can be increased to 300 mg once daily in patients tolerating
INVOKANA 100 mg once daily who have an eGFR of 60 mL/min/1.73 m2
or greater and require additional glycemic control (2.1)
!INVOKANA is limited to 100 mg once daily in patients who have an
eGFR of 45 to less than 60 mL/min/1.73 m2 (2.2)
!Assess renal function before initiating INVOKANA. Do not initiate
INVOKANA if eGFR is below 45 mL/min/1.73 m2 (2.2)
!Discontinue INVOKANA if eGFR falls below 45 mL/min/1.73 m2 (2.2)
----------------------DOSAGE FORMS AND STRENGTHS---------------------
Tablets: 100 mg, 300 mg (3)
-------------------------------CONTRAINDICATIONS-------------------------------
!History of serious hypersensitivity reaction to INVOKANA (4)
!Severe renal impairment, ESRD, or on dialysis (4)
---------------------------WARNINGS AND PRECAUTIONS--------------------
! Hypotension: Before initiating INVOKANA, assess volume status and
correct hypovolemia in patients with renal impairment, the elderly, in
patients with low systolic blood pressure, or if on diuretics, ACEi, or ARB.
Monitor for signs and symptoms during therapy (5.1)
! Impairment in Renal Function: Monitor renal function during therapy.
More frequent monitoring is recommended in patients with eGFR below
60 mL/min/1.73 m2 (5.2)
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
2.2 Patients with Renal Impairment
2.3 Concomitant Use with UDP-Glucuronosyl
Transferase (UGT) Enzyme Inducers
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hypotension
5.2 Impairment in Renal Function
5.3 Hyperkalemia
5.4 Hypoglycemia with Concomitant Use with Insulin
and Insulin Secretagogues
5.5 Genital Mycotic Infections
5.6 Hypersensitivity Reactions
5.7 Increases in Low-Density Lipoprotein (LDL-C)
5.8 Macrovascular Outcomes
6 ADVERSE REACTIONS
6.1 Clinical Studies Experience
7 DRUG INTERACTIONS
7.1 UGT Enzyme Inducers
7.2 Digoxin
7.3 Positive Urine Glucose Test
7.4 Interference with 1,5-anhydroglucitol (1,5-AG)
Assay ! Hyperkalemia: Monitor potassium levels in patients with impaired renal function and in patients predisposed to hyperkalemia (5.3) ! Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA (5.4) ! Genital mycotic infections: Monitor and treat if indicated (5.5) ! Hypersensitivity reactions: Discontinue INVOKANA and monitor until signs and symptoms resolve (5.6) ! Increased LDL-C: Monitor LDL-C and treat per standard of care (5.7) ------------------------------ADVERSE REACTIONS-------------------------------! Most common adverse reactions associated with INVOKANA (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or doc.guandang.net INTERACTIONS-------------------------------! UGT inducers (e.g., rifampin): Canagliflozin exposure is reduced. Consider increasing dose from 100 mg to 300 mg (2.3, 7.1) ! Digoxin: Monitor digoxin levels (7.2) -----------------------USE IN SPECIFIC POPULATIONS------------------------! Pregnancy: No adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus (8.1) ! Nursing mothers: Discontinue drug or nursing (8.3) ! Geriatrics: Higher incidence of adverse reactions related to reduced intravascular volume (5.1, 8.5) ! Renal impairment: Higher incidence of adverse reactions related to reduced intravascular volume and renal function ( 2.2, 5.2, 8.6) ! Hepatic impairment: Not recommended with severe hepatic impairment (8.7) See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: XX/2013 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13.2 Animal Toxicology and/or Pharmacology 14 CLINICAL STUDIES 14.1 Monotherapy 14.2 Combination Therapy 14.3 Studies in Special Populations 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed
1
坎格列净片环境评价_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 坎格列净片环境评价_医药卫生_专业资料。坎格列净片今日推荐 ...
坎格列净片OFFICE DIRECTOR MEMO_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 坎格列净片OFFICE DIRECTOR MEMO_医药卫生_专业资料。坎格列净片...
达格列净片 FARXIGA (dapagliflozin) FDA药品说明书翻译_医药卫生_专业资料。定期提供最近FDA说明书翻译,纯手工翻译。FULL PRESCRIBING INFORMATION 1 INDICATIONS AND...
卡格列净(坎格列净)canagliflozin杂质列表_医药卫生_专业资料。深圳卓越生物 为您提供标准品,杂质对照品,原研参比制剂等卡格列净/坎格列净 canagliflozin 杂质列表...
米拉贝隆片说明书简化版_医药卫生_专业资料。米拉贝隆片HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ...
氯吡格雷相关杂质C、坎格列净、L-天门冬氨酸医用...3.交期说明:根据对方订单要求。 4.付款条件:全款... 科目三实际道路驾驶考试注意事项 驾考新题抢先版...
Farxiga(dapagliflozin,达格列净片)说明书_临床医学_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 Farxiga(dapagliflozin,达格列净片)说明书_临床医学_医药...
sel551说明书简化版_电力/水利_工程科技_专业资料。SEL-551 产品用户手册 P1...订货时可要求预配线 接地端子(端子 Z09) :引片尺寸为 0.25"×0.032",...
D2008F 系列 数字式电子称重仪表 技术说明书 2010 年 09 月简化版 ●使用前请仔细阅读本产品说明书 ●请妥善保管本产品说明书,以备查阅 I 目 录 第一章 技术...
消毒产品标签说明书管理规范陈 妍 广州市卫生监督所传染病防治科 对消毒产品标签说明书检查过程中发现的普遍问题 ? 未列入消毒产品分类目录的产品标注与消毒 产品有...
热门文档